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PDiscussion
Dr Bartley P. Griffith (Baltimore, Md). Dr Iglesias and Dr Mac-
chiarini, I thank you for what may be a paradigm-shifting manu-
script that may in fact change practice to a great degree in this
terrible postoperative complication.
[Slides] Some time ago I was interested in the laboratory with
pursuing arteriovenous extracorporeal membrane oxygenation as
an artificial placenta to mature newborn lamb lungs. We did not rec-
ognize then the importance of barotrauma, and we evaluated the
shunt required to normalize PO2. We early learned that by increasing
the shunt, we could change PO2, but the numbers required to do that
required a great strain on the heart.
The importance of this paper has been to confirm the concept that
Gattinoni brought to us of the ‘‘baby lung.’’ We must remember the
ARDS patient shown on this computed tomographic scan, the im-
portance of the defunctionalized lung that does not ventilate as op-
posed to the ventilated lung, which may be as little as a third of each
lung. Sixty-six percent of this patient’s lung would not be ventilated
and 33% would be ventilated, so even at a reserved low-volume
ventilation, that translates into about 18 mL/kg or high ventilation
volume to the normally ventilated lung, which we know from
ARDSNet to be counterproductive.
You have appropriately dissociated oxygenation andMV.Extrap-
ulmonary gas exchange replaces MV, which enables a therapeutic
window to protect the ventilation. The key to your study, of course,
is the low-resistance oxygenator that is now commercially available
in Europe and the fact that less than 20% of the CO needs to be
diverted into this oxygenator to achieve almost 300 mL of carbon
dioxide removal. While you ventilated with a PEEP of 19, your
end-inspiratory pressure was only 21. Your tidal volume was a third
of the ‘‘optimized’’ ventilated group and a fifth of the conventionally
ventilated group. Your minute volume was only 1 L, at a rate of 6.
Your model probably is not the same that we see clinically withThe Journal of ThorappARDS, but that is okay. I think what you have demonstrated is
lungprotection,which is thehallmark of treating this terrible problem.
I have two questions for you. Have you looked at various forms
of ventilation of your animals that might in fact even improve on the
outcomes that you had with the current experimental group? In other
words, have you tried continuous positive airway pressure as a ven-
tilatory method for these animals, extubating them very early?
Finally, have you measured cytokines in animals that did not
have anything other than the iLA associated with it? Early on in
my career, there was a lot of criticism about using artificial lung
membranes in patients with injured lungs for fear that cytokines
would in fact be elaborated.
Dr Iglesias. Thank you for your questions. To address the sec-
ond question, I performed a study accepted in the Journal of Tho-
racic and Cardiovascular Surgery where we placed the iLA in
axillary vascular access and then wemeasured the cytokine response
and did not find a systemic inflammatory response in this type of
pigs. It was done undergoing nothing for us. It practically inhaled
the pigs.
I did not understand your first question.
Dr Griffith. Could you forecast perhaps an even better form of
assisted ventilation to work in concert with the iLA, such as sponta-
neous continuous positive airway pressure?
Dr Iglesias. I refer this question to Dr Macchiarini.
DrMacchiarini. Thank you for the question. Yes, we did, in the
sense that as soon as you get on the iLA, you need to adapt the ven-
tilation and try the best setting in the sense that some respond very
well to pressure control and some to volume control. We found that
for the type of pneumonectomy that we did, a very simple pneumo-
nectomy, the pressure control ventilation was the simplest to man-
age. Whether or not this was because we had such a high level of
PEEP, I cannot tell you that, but it is a little bit parallel to what
we saw in the clinical experience on severe ppARDS. I would sug-
gest that from the experimental and clinical experience, so long as
you reach the target to reduce the tidal volumes as low as you
can, you might use either of the ventilation modes. We can go
even further. We tried to not ventilate the patients at all in the clinical
setting but simply keeping in place the tracheostomy tube or the tra-
cheal tube and putting a very low flow of oxygen, doing a sort of
apneic oxygenation. It did work as well. So there is a very large
variability among patients. Youmight try to use the best one adapted
to the patient, as long as you reach very low tidal volumes.
Dr Nasser K. Altorki (New York, NY). How long were the pigs
generally treated on the extracorporeal membrane oxygenator?
Were they also on some ancillary measures, such as steroids, or
were they just treated simply by the oxygenator?
Dr Iglesias. We treated with iLA in a total of 5 pigs among the
15 pigs in which we induced ARDS by surfactant depletion.
Dr Altorki. How many days were they on it after the ARDS
induction?
Dr Iglesias. Ninety minutes, more or less.cic and Cardiovascular Surgery c Volume 135, Number 6 1371
